Showing 1,301 - 1,320 results of 27,685 for search '(( 50 ((ng decrease) OR (we decrease)) ) OR ( 100 ((mean decrease) OR (a decrease)) ))', query time: 1.00s Refine Results
  1. 1301

    Sequence of <i>DpAP2</i> promoter. by Lingru Ruan (18995544)

    Published 2024
    “…<i>parva</i> cells treated with different concentrations of MeJA (10, 20, 50, 100 μM) and GA3 (10, 20, 50, 100 μM). The high concentrations of MeJA (10–100 μM) inhibited the accumulation of carotenoid, and the relative expression of <i>DpAP2</i>, <i>PSY</i>, <i>PDS</i> and <i>GGPS</i> decreased significantly. …”
  2. 1302

    Predicted <i>cis</i>-acting elements in <i>DpAP2</i> promoter. by Lingru Ruan (18995544)

    Published 2024
    “…<i>parva</i> cells treated with different concentrations of MeJA (10, 20, 50, 100 μM) and GA3 (10, 20, 50, 100 μM). The high concentrations of MeJA (10–100 μM) inhibited the accumulation of carotenoid, and the relative expression of <i>DpAP2</i>, <i>PSY</i>, <i>PDS</i> and <i>GGPS</i> decreased significantly. …”
  3. 1303
  4. 1304
  5. 1305
  6. 1306
  7. 1307
  8. 1308
  9. 1309

    Datasheet1_Acquired von Willebrand syndrome (AVWS) type 2, characterized by decreased high molecular weight multimers, is common in children with severe pulmonary hypertension (PH)... by Ivonne Wieland (14112981)

    Published 2022
    “…Hemostatic complications were observed in 4 of 12 (33%) patients with VWS and 3 of 6 (50%) patients without diagnostics and therapy.</p>Conclusion<p>For children with moderate to severe PH, we recommend systematic analysis of von Willebrand variables, including multimer analysis, PFA-100 and platelet function testing. …”
  10. 1310
  11. 1311

    Delphinidin alters VEGF-A splicing to increase VEGF-A<sub>165</sub>b and decrease total VEGF-A expression. by Megan Stevens (3964886)

    Published 2019
    “…<p><b>A)</b> Treatment of podocytes with delphinidin chloride (10 μg/ml) under normal glucose (NG; 5 mM glucose + 25 mM mannitol) and high glucose (HG; 30 mM glucose, 1 ng/ml TNFα, 1 ng/ml IL-6, and 100 nM insulin) for 48 hrs increased the protein expression of VEGF-A<sub>165</sub>b relative to total VEGF-A<sub>165</sub> (quantified in <b>B</b>; *p<0.05 vs NG, †p<0.05 vs HG; n = 3 biological repeats; One-way ANOVA with Bonferroni post-hoc test for comparison between pairs; <b>A</b>—the same blot was first probed with VEGF-A<sub>165</sub>b before stripping and reprobing with panVEGF-A). …”
  12. 1312

    Table 1_Atractylenolide-I restore intestinal barrier function by targeting the S100A9/AMPK/mTOR signaling pathway.xlsx by Chen Chen (6544)

    Published 2025
    “…Mechanistically, recombinant human S100A9 protein was found to induce a decrease in intracellular Ca<sup>2+</sup> concentration, while AT-1 regulated the expression of tight junction proteins via modulation of the AMPK/mTOR signaling pathway. …”
  13. 1313

    Image 2_Atractylenolide-I restore intestinal barrier function by targeting the S100A9/AMPK/mTOR signaling pathway.tif by Chen Chen (6544)

    Published 2025
    “…Mechanistically, recombinant human S100A9 protein was found to induce a decrease in intracellular Ca<sup>2+</sup> concentration, while AT-1 regulated the expression of tight junction proteins via modulation of the AMPK/mTOR signaling pathway. …”
  14. 1314

    Image 1_Atractylenolide-I restore intestinal barrier function by targeting the S100A9/AMPK/mTOR signaling pathway.tif by Chen Chen (6544)

    Published 2025
    “…Mechanistically, recombinant human S100A9 protein was found to induce a decrease in intracellular Ca<sup>2+</sup> concentration, while AT-1 regulated the expression of tight junction proteins via modulation of the AMPK/mTOR signaling pathway. …”
  15. 1315
  16. 1316
  17. 1317
  18. 1318
  19. 1319

    ApoA-I inhibits leukocyte adhesion to endothelial cells <i>in vivo</i>. by Scott J. Cameron (838315)

    Published 2015
    “…(B) ApoA-I knockout mice (apoA-I <sup>-/-</sup>) have low plasma HDL concentration compared to WT mice and show increased adhesion of leukocytes to the vascular endothelium <i>in vivo</i> (decreased rolling velocity) compared to WT mice or apoA-I <sup>-/-</sup> mice injected with apo-AI (0.5mg, intraperitoneal) 24 hours before. …”
  20. 1320